Characteristics of Patients Treated With Biologic Agents for Moderate-to-Severe Atopic Dermatitis in Poland
Author(s)
Witold Owczarek, Prof1, Irena Walecka-Herniczek, Prof2, Gerald Waligora, MSc1, Michal Pochopien, MSc, PhD3, Anna Lanecka, MSc4, Michal Gorecki, MSc4.
1Military Institute of Medicine, Warsaw, Poland, 2National Medical Institute of the Ministry of the Interior and Administration, Warsaw, Poland, 3Clever-Access, Paris, France, 4Clever-Access, Krakow, Poland.
1Military Institute of Medicine, Warsaw, Poland, 2National Medical Institute of the Ministry of the Interior and Administration, Warsaw, Poland, 3Clever-Access, Paris, France, 4Clever-Access, Krakow, Poland.
OBJECTIVES: The purpose of this study was to analyse the characteristics of patients treated with biologic agents for moderate-to-severe atopic dermatitis in Poland.
METHODS: A comprehensive dataset from the B.124 “Treatment of patients with atopic dermatitis (ICD-10: L20)” drug program, including 2,319 patients treated from 2022 up to January 2025, was analysed. The dataset provided patient characteristics such as demographic information, dates of qualification to the program, together with counselling visit dates, medications used, and health outcomes at the counselling visits. The changes in inclusion criteria and treatment availability over the years were analysed. The baseline characteristics including patients’ age, disease severity measured with Eczema Area and Severity Index (EASI) and quality of life measured with Dermatology Life Quality Index (DLQI) were studied.
RESULTS: A total of 2,319 patients were enrolled in the program. In 2022, 349 patients were introduced to the study. In the following two years, 897 and 1,063 patients were included, respectively. Among all patients, 52.2% were male, with an average age of 34.2 years. EASI score of patients at baseline was 31.1 and the DLQI score was 20.3, indicating severe impact of the disease on the patients' lives.In 2022, only three treatments were available: 93.7% of patients were treated with dupilumab, 5.4% with upadacitinib, and 0.9% with baricitinib. The following year, abrocitinib and tralokinumab were introduced, with 0.3% and 0.2% of patients receiving these treatments in 2023, respectively. In 2024 the distribution of treatments was as follows: dupilumab (58.2%), tralokinumab (21%), upadacitinib (14.8%), abrocitinib (4%), and baricitinib (2.1%).
CONCLUSIONS: The conditions of the B.124 drug program underwent significant changes over the years of its operation. The overall baseline characteristics of the patients were similar across the different treatments.
METHODS: A comprehensive dataset from the B.124 “Treatment of patients with atopic dermatitis (ICD-10: L20)” drug program, including 2,319 patients treated from 2022 up to January 2025, was analysed. The dataset provided patient characteristics such as demographic information, dates of qualification to the program, together with counselling visit dates, medications used, and health outcomes at the counselling visits. The changes in inclusion criteria and treatment availability over the years were analysed. The baseline characteristics including patients’ age, disease severity measured with Eczema Area and Severity Index (EASI) and quality of life measured with Dermatology Life Quality Index (DLQI) were studied.
RESULTS: A total of 2,319 patients were enrolled in the program. In 2022, 349 patients were introduced to the study. In the following two years, 897 and 1,063 patients were included, respectively. Among all patients, 52.2% were male, with an average age of 34.2 years. EASI score of patients at baseline was 31.1 and the DLQI score was 20.3, indicating severe impact of the disease on the patients' lives.In 2022, only three treatments were available: 93.7% of patients were treated with dupilumab, 5.4% with upadacitinib, and 0.9% with baricitinib. The following year, abrocitinib and tralokinumab were introduced, with 0.3% and 0.2% of patients receiving these treatments in 2023, respectively. In 2024 the distribution of treatments was as follows: dupilumab (58.2%), tralokinumab (21%), upadacitinib (14.8%), abrocitinib (4%), and baricitinib (2.1%).
CONCLUSIONS: The conditions of the B.124 drug program underwent significant changes over the years of its operation. The overall baseline characteristics of the patients were similar across the different treatments.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
RWD28
Topic
Clinical Outcomes, Real World Data & Information Systems
Topic Subcategory
Health & Insurance Records Systems
Disease
Biologics & Biosimilars, Sensory System Disorders (Ear, Eye, Dental, Skin)